Guangdong Zhongsheng Pharmaceutical Co., Ltd.
002317
Rangering i aksjer
#4568
Guangdong Zhongsheng Pharmaceutical Co., Ltd. is a Chinese pharmaceutical... Guangdong Zhongsheng Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company actively involved in the entire lifecycle of drug development, from research and development to manufacturing and commercialization. Its product portfolio encompasses both traditional Chinese medicines (TCM) and modern chemical pharmaceuticals. The company's robust research and development initiatives are directed towards creating solutions for a wide array of health conditions, specifically targeting ophthalmological, cardiovascular, cerebrovascular, respiratory, digestive, diabetic, oncological, and age-related degenerative diseases. Established in 1979, the company maintains its primary operations from its headquarters in Dongguan, China.
Aksjekurs
$3.89
Markedsverdi
$3.30B
Endring (1 dag)
-3.14%
Endring (1 år)
43.11%
Land
CN
Handel Guangdong Zhongsheng Pharmaceutical Co., Ltd. (002317)
Kategori
Healthcare
Inntekter for Guangdong Zhongsheng Pharmaceutical Co., Ltd. (002317)
Inntekter i Jun 2026 TTM: $30.61M
Ifølge Guangdong Zhongsheng Pharmaceutical Co., Ltd. sine nyeste økonomiske rapporter er selskapets nåværende resultat $30.61M. I 2024 hadde selskapet et resultat på $-46.02M, en nedgang sammenlignet med resultatet i 2023, som var $40.07M. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Guangdong Zhongsheng Pharmaceutical Co., Ltd. fra 2006 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $30.61M | -27.78% |
| 2025 | $42.39M | -192.12% |
| 2024 | $-46.02M | -214.83% |
| 2023 | $40.07M | -24.95% |
| 2022 | $53.39M | 9.66% |
| 2021 | $48.69M | -192.13% |
| 2020 | $-52.85M | -197.14% |
| 2019 | $54.41M | -25.14% |
| 2018 | $72.68M | -3.83% |
| 2017 | $75.58M | 8.55% |
| 2016 | $69.62M | 32.24% |
| 2015 | $52.65M | 31.36% |
| 2014 | $40.08M | 11.54% |
| 2013 | $35.94M | 5.30% |
| 2012 | $34.13M | 22.83% |
| 2011 | $27.78M | 19.74% |
| 2010 | $23.20M | 38.06% |
| 2009 | $16.81M | 34.21% |
| 2008 | $12.52M | 76.32% |
| 2007 | $7.10M | 52.00% |
| 2006 | $4.67M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $3.62B | 11,717.83% |
DE
|
|
| $3.40B | 11,022.45% |
DE
|
|
| $1.72B | 5,530.23% |
JP
|
|
| $930.30M | 2,938.85% |
CH
|
|
| $1.69B | 5,429.10% |
IN
|
